The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia
Authors:
- Fanny LegrandFLFanny Legrand
- Aline RennevilleARAline Renneville
- Elizabeth MacIntyreEMElizabeth MacIntyre
- Samuel MastrilliSMSamuel Mastrilli
- Felix AckermannFAFelix Ackermann
- Jean Michel CayuelaJCJean Michel Cayuela
- Philippe RousselotPRPhilippe Rousselot
- Aline Schmidt-TanguyASAline Schmidt-Tanguy
- Olivier FainOFOlivier Fain
- Marc MichelMMMarc Michel
- Jean-Pierre de JaureguiberryJJJean-Pierre de Jaureguiberry
- Pierre-Yves HatronPHPierre-Yves Hatron
Open Access
- 1 September 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 92 (5) , e1-e9
Abstract
Imatinib is the treatment of choice for FIP1L1/PDGFRA (F/P)-associated chronic eosinophilic leukemia (F/P+ CEL), but its optimal dosing, duration, and possibility of discontinuation are still a matter of debate. A retrospective multicenter study was conducted with 44 F/P+ CEL patients identified in the French Eosinophil Network and treated with imatinib. The most frequently involved systems were skin (57%), spleen (52%), and lung (45%), and eosinophilic heart disease was observed in 15 patients (34%). Complete hematologic response (CHR) was obtained in all patients, and complete molecular response (CMR) in 95% of patients (average initial imatinib dose, 165 mg/d). For 29 patients the imatinib dose was tapered with a maintenance dose of 58 mg/d (±34 mg/d), allowing sustained CHR and CMR. None of the patients developed resistance during a median follow-up of 52.3 months (range, 1.4–97.4 mo). Imatinib was stopped in 11 patients; 6 of the patients subsequently relapsed, but 5 remained in persistent CHR or CMR (range, 9–88 mo). These results confirm that an initial low-dose regimen of imatinib (100 mg/d) followed by a lower maintenance dose can be efficient for obtaining long-term CHR and CMR. Our data also suggest that imatinib can be stopped in some patients without molecular relapse.Keywords
This publication has 31 references indexed in Scilit:
- Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatmentBlood, 2011
- Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylatePediatric Blood & Cancer, 2010
- Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapyJournal of Allergy and Clinical Immunology, 2009
- Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1‐PDGFRA fusion transcript—results of Polish multicentre studyHematological Oncology, 2009
- Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1‐PDGFRA fusion transcript: extended follow‐upBritish Journal of Haematology, 2009
- Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosingBlood, 2007
- WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemiaLeukemia, 2007
- Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogeneticsLeukemia, 2005
- Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemiasLeukemia, 2004
- Distinction of eosinophilic leukaemia from idiopathic hypereosinophilic syndrome by analysis of Wilms' tumour gene expressionBritish Journal of Haematology, 1998